Background Background Treatment options for
Treatment options for depression include antidepressants, depression include antidepressants, psychological therapy and a combination psychological therapy and a combination of the two. of the two.
Aims Aims To develop cost-effective clinical
To develop cost-effective clinical guidelines. guidelines.
Method
Method Systematic literature reviews Systematic literature reviews were used to identify clinical, utility and were used to identify clinical, utility and cost data. A decision analysis was then cost data. A decision analysis was then conducted to compare the benefits and conducted to compare the benefits and costs of antidepressants with combination costs of antidepressants with combination therapy for moderate and severe therapy for moderate and severe depression in secondary care in the UK. depression in secondary care in the UK.
Results

Results Over the15-month analysis
Over the15-month analysis period, combination therapy resulted in period, combination therapy resulted in higher costs and an expected 0.16 increase highercosts and an expected 0.16 increase per person in the probability of remission per person in the probability of remission and no relapse compared with and no relapse compared with antidepressants.The cost per additional antidepressants.The cost per additional successfully treated patient was »4056 successfully treated patient was »4056 (95% CI1400^18 300); the cost per (95% CI1400^18 300); the cost per quality-adjusted life year gained was quality-adjusted life year gained was »5777 (95% CI1900^33 800) for severe »5777 (95% CI1900^33 800) for severe depression and »14 540 (95% CI 4800depression and »14 540 (95% CI 48007 9 400) for moderate depression. 79 400) for moderate depression.
Conclusions Conclusions Combination therapy is
Combination therapy is likely to be a cost-effective first-line likely to be a cost-effective first-line secondary care treatment for severe secondary care treatment for severe depression.Its cost-effectiveness for depression.Its cost-effectiveness for moderate depression is more uncertain moderate depression is more uncertain from current evidence.Targeted from current evidence.Targeted combination therapy could improve combination therapy could improve resource utilisation. resource utilisation.
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Depression is the most common psychiatric Depression is the most common psychiatric disorder and the fourth major cause of disdisorder and the fourth major cause of disease burden worldwide (World Health ease burden worldwide (World Health Organization, 2001 ). In the UK, one in four Organization, 2001 ). In the UK, one in four women and one in ten men experience at women and one in ten men experience at least one episode of depression requiring least one episode of depression requiring treatment during their lifetime (National treatment during their lifetime (National Depression Campaign, 1999 ) and more Depression Campaign, 1999) and more than half of these will have at least one than half of these will have at least one more episode (Kupfer, 1991) . Treatment more episode (Kupfer, 1991) . Treatment options for moderate and severe depression options for moderate and severe depression include pharmacotherapy, psychological include pharmacotherapy, psychological therapy and the combination of the two. therapy and the combination of the two. Since these strategies have different reSince these strategies have different resource requirements and their availability source requirements and their availability may vary significantly, it is important to may vary significantly, it is important to evaluate not only their benefits and risks evaluate not only their benefits and risks but also their cost-effectiveness. This paper but also their cost-effectiveness. This paper presents an updated version of a decision presents an updated version of a decision analysis developed for the National analysis developed for the National Institute for Clinical Excellence (2004) Institute for Clinical Excellence (2004) depression guideline to evaluate the outdepression guideline to evaluate the outcomes and likely costs of the first-line use comes and likely costs of the first-line use of antidepressant medication or combinaof antidepressant medication or combination therapy for moderate and severe detion therapy for moderate and severe depression in secondary care in the UK pression in secondary care in the UK (National Collaborating Centre for Mental (National Collaborating Centre for Mental Health, 2005) . Health, 2005).
METHOD METHOD
There has been little research on the comThere has been little research on the comparative cost-effectiveness of antidepressant parative cost-effectiveness of antidepressant therapy and combination therapy. We therapy and combination therapy. We could identify in the international literature could identify in the international literature only one study, a trial-based economic evalu only one study, a trial-based economic evalu--ation, but this assessed cost-effectiveness ation, but this assessed cost-effectiveness of combination therapy for relapse prevenof combination therapy for relapse prevention for patients with residual depression tion for patients with residual depression (Scott (Scott et al et al, 2003) . No estimate exists, how-, 2003) . No estimate exists, however, for the likely outcomes and costs of ever, for the likely outcomes and costs of the routine use of different treatment stratethe routine use of different treatment strategies for patients with moderate and severe gies for patients with moderate and severe depression in secondary care. Therefore, a depression in secondary care. Therefore, a pragmatic decision analytic model was depragmatic decision analytic model was developed to compare the effectiveness and veloped to compare the effectiveness and costs of using antidepressant therapy alone costs of using antidepressant therapy alone with using combination therapy for people with using combination therapy for people with moderate and severe depression over with moderate and severe depression over a 15-month period (3-month initial treata 15-month period (3-month initial treatment and 12-month follow-up, no maintement and 12-month follow-up, no maintenance therapy) (Fig. 1) . These time nance therapy) (Fig. 1 ). These time horizons were chosen to be most similar horizons were chosen to be most similar to the available comparative clinical evito the available comparative clinical evidence. All analyses were carried out in dence. All analyses were carried out in Microsoft Excel (2003 release).
Microsoft Excel (2003 release).
Clinical effectiveness data were obClinical effectiveness data were obtained from a wider review of psychological tained from a wider review of psychological therapies for the treatment of depression therapies for the treatment of depression undertaken to support the development of undertaken to support the development of the National Institute for Clinical Excelthe National Institute for Clinical Excellence (NICE) clinical guideline (National lence (NICE) clinical guideline (National Collaborating Centre for Mental Health, Collaborating Centre for Mental Health, 2005) . This recommends cognitive-2005) . This recommends cognitivebehavioural therapy and interpersonal therbehavioural therapy and interpersonal therapy as psychological therapies in the treatapy as psychological therapies in the treatment of moderate and severe depression. ment of moderate and severe depression. We chose cognitive-behavioural therapy We chose cognitive-behavioural therapy for our analysis since it has a relatively for our analysis since it has a relatively B R I T I S H J O UR N A L O F P SYC HI AT RY B R I T I S H J O UR N A L O F P S YC H I AT RY ( 2 0 0 6 ) , 1 8 9, 4 9 4^5 0 1. d o i : 1 0 . 11 9 2 / b j p . b p . 1 0 5 . 0 1 4 5 7 1 ( 2 0 0 6 ) , 1 8 9, 4 9 4^5 0 1 . d o i : 1 0 .11 9 2 / b j p . the randomisation method used was the randomisation method used was unbiased so that each participant stood an unbiased so that each participant stood an equal chance of being allocated to any equal chance of being allocated to any group and the allocated group could not group and the allocated group could not be known before allocation took place) be known before allocation took place) and efficacy ratings were undertaken by a and efficacy ratings were undertaken by a masked assessor. Trials in which some parmasked assessor. Trials in which some participants had a primary diagnosis of bipolar ticipants had a primary diagnosis of bipolar disorder or dysthymia rather than a pridisorder or dysthymia rather than a primary diagnosis of (unipolar) major depresmary diagnosis of (unipolar) major depressive disorder were included provided the sive disorder were included provided the proportion with the alternative diagnosis proportion with the alternative diagnosis did not exceed 15% for bipolar disorder did not exceed 15% for bipolar disorder or 20% for dysthymia (figures arrived at or 20% for dysthymia (figures arrived at through consultation with the Guideline through consultation with the Guideline Development Group). In addition, study Development Group For the current analysis, clinical eviFor the current analysis, clinical evidence on the effectiveness of individual dence on the effectiveness of individual cognitive-behavioural therapy in combinacognitive-behavioural therapy in combination with antidepressants compared with tion with antidepressants compared with antidepressant therapy alone in patients antidepressant therapy alone in patients with moderate and severe depression was with moderate and severe depression was synthesised using meta-analysis. Efficacy synthesised using meta-analysis. Efficacy data were extracted and entered into data were extracted and entered into Review Manager software version 4.2.3 Review Manager software version 4.2.3 (Cochrane Collaboration) by one reviewer (Cochrane Collaboration) by one reviewer (R.B.) and checked by another (Preethi (R.B.) and checked by another (Preethi Premkumar or Lisa Underwood). Relapse Premkumar or Lisa Underwood). Relapse data used in this analysis were extracted data used in this analysis were extracted by J.S. Data were not extracted if more by J.S. Data were not extracted if more than 50% of a treatment group left treatthan 50% of a treatment group left treatment for whatever reason, to preserve the ment for whatever reason, to preserve the robustness of the estimated effect sizes. robustness of the estimated effect sizes. Data were extracted on an intention-toData were extracted on an intention-totreat basis so that participants who did treat basis so that participants who did not complete the study protocol were treanot complete the study protocol were treated as having the least favourable outcome. ted as having the least favourable outcome. Data were pooled using a fixed-effects Data were pooled using a fixed-effects model (Hedges & Olkin, 1985) , unless sigmodel (Hedges & Olkin, 1985) , unless significant heterogeneity was present (defined nificant heterogeneity was present (defined as as I I 2 2 4 450%) that could not be explained 50%) that could not be explained by sensitivity analyses (for example, based by sensitivity analyses (for example, based on differences in study methodology), when on differences in study methodology), when a random effects model was used (DerSia random effects model was used (DerSimonian & Laird, 1986; Higgins & Thompmonian & Laird, 1986; Higgins & Thompson, 2002 ). Risk differences were calculated son, 2002). Risk differences were calculated for the various effectiveness measures tofor the various effectiveness measures together with their 95% confidence intervals. gether with their 95% confidence intervals.
Outcomes Outcomes
The number of patients treated successfully The number of patients treated successfully (remission and no relapse over a 12-month (remission and no relapse over a 12-month follow-up period) was chosen as the prifollow-up period) was chosen as the primary outcome measure for the decision mary outcome measure for the decision analysis. Remission was defined as reaching analysis. Remission was defined as reaching scores 6 or less on the 17-item HRSD or 8 scores 6 or less on the 17-item HRSD or 8 or less on the 24-item HRSD during treator less on the 24-item HRSD during treatment. Patients with unsuccessful treatment ment. Patients with unsuccessful treatment outcomes included those who did not comoutcomes included those who did not complete the 3-month treatment, those who plete the 3-month treatment, those who completed the treatment but without completed the treatment but without remission, and those who relapsed during remission, and those who relapsed during follow-up. follow-up.
Patients with moderate or severe Patients with moderate or severe depression could differ substantially in their depression could differ substantially in their health-related quality of life, so we also health-related quality of life, so we also looked at health benefits in terms of looked at health benefits in terms of quality-adjusted life-years (QALYs) gained. quality-adjusted life-years (QALYs) gained. This generic outcome measure permits This generic outcome measure permits comparison of results between disease areas comparison of results between disease areas and also complies with current methodand also complies with current methodological guidance by NICE (Richardson ological guidance by NICE (Richardson et et al al, 2004) . Quality-adjusted life-years were , 2004). Quality-adjusted life-years were calculated using the combination of calculated using the combination of quality-of-life weights with the estimated quality-of-life weights with the estimated length of time patients spend in the correlength of time patients spend in the corresponding health states through the different sponding health states through the different clinical pathways in the decision model. clinical pathways in the decision model. The quality-of-life weights were obtained The quality-of-life weights were obtained by a systematic review of the economic by a systematic review of the economic evidence of depression. Details of the ecoevidence of depression. Details of the economic literature review are reported elsenomic literature review are reported elsewhere (National Collaborating Centre for where (National Collaborating Centre for Mental Health, 2005) . Here we present Mental Health, 2005). Here we present only identified evidence relevant to the only identified evidence relevant to the current study. Table 1 lists all the clinical current study. Table 1 lists all the clinical effectiveness estimates and quality-of-life effectiveness estimates and quality-of-life weights used in the decision analysis. weights used in the decision analysis.
Costs and cost-effectiveness Costs and cost-effectiveness
Since no patient-level data were available to Since no patient-level data were available to calculate costs in the model, deterministic calculate costs in the model, deterministic costing of the different treatment strategies costing of the different treatment strategies was carried out. Costs were identified from was carried out. Costs were identified from the perspective of the NHS and expressed the perspective of the NHS and expressed in UK £ at 2002-3 prices. We calculated in UK £ at 2002-3 prices. We calculated the cost of the initial treatment protocols the cost of the initial treatment protocols (medication costs, staff costs, dispensing (medication costs, staff costs, dispensing fees) using resource use estimates based on fees) using resource use estimates based on both the expert opinion of the Guideline both the expert opinion of the Guideline Development Group and the literature. Development Group and the literature. The cost of the likely subsequent healthcare The cost of the likely subsequent healthcare resource use for the 15-month analysis resource use for the 15-month analysis period was based on estimates obtained period was based on estimates obtained from the systematic review of the economic from the systematic review of the economic evidence. , prescribed as part of standard outpatient care with an average of four speciapatient care with an average of four specialist visits, assuming two visits by a consullist visits, assuming two visits by a consultant and two visits by a specialist registrar tant and two visits by a specialist registrar (expert opinion of the Guideline Develop-(expert opinion of the Guideline Development Group). Fluoxetine was advocated ment Group). Fluoxetine was advocated as the best antidepressant to represent rouas the best antidepressant to represent routine pharmacotherapy for patients with tine pharmacotherapy for patients with moderate or severe depression because, as moderate or severe depression because, as with other selective serotonin reuptake with other selective serotonin reuptake inhibitors, it has low toxicity in overdose inhibitors, it has low toxicity in overdose compared with other classes of antideprescompared with other classes of antidepressant (Freemantle sant (Freemantle et al et al, 1994) . It was also , 1994). It was also the most widely prescribed antidepressant the most widely prescribed antidepressant Combination therapy was defined as Combination therapy was defined as the combined use of the antidepressant the combined use of the antidepressant treatment protocol (described above) treatment protocol (described above) and cognitive-behavioural therapy for a and cognitive-behavioural therapy for a 3-month period. A full course of 3-month period. A full course of cognitive-behavioural therapy included 16 cognitive-behavioural therapy included 16 sessions, each session lasting for an average sessions, each session lasting for an average of 50 min (McCullough, 1995) . Based on of 50 min (McCullough, 1995) . Based on the expert opinion of the Guideline the expert opinion of the Guideline Development Group, clinical psychologists Development Group, clinical psychologists were used as the most representative examwere used as the most representative example of therapists providing this treatment in ple of therapists providing this treatment in the UK. Such a treatment strategy was also the UK. Such a treatment strategy was also in line with the treatment protocols of the in line with the treatment protocols of the reviewed clinical studies. reviewed clinical studies.
To calculate the cost of the initial treatTo calculate the cost of the initial treatment, we combined the estimated resource ment, we combined the estimated resource use with UK-specific unit costs obtained use with UK-specific unit costs obtained from the from the BNF BNF tion Pricing Authority (http://www.ppa. gov.uk). Although occasionally missed gov.uk). Although occasionally missed treatment sessions meant that full costs treatment sessions meant that full costs were incurred, treatment costs were revised were incurred, treatment costs were revised to account for patients who did not comto account for patients who did not complete the treatment. For this, it was plete the treatment. For this, it was assumed that patients who discontinue inassumed that patients who discontinue initial therapy have on average 3 weeks of itial therapy have on average 3 weeks of treatment (Elkin treatment (Elkin et al et al, 1989; expert opinion , 1989 ; expert opinion of the Guideline Development Group). of the Guideline Development Group). Patients in remission who do not relapse Patients in remission who do not relapse 1986) . All unit cost para-, 1986). All unit cost parameters used in the evaluation are reported meters used in the evaluation are reported in Table 1 . Total costs of the different clinin Table 1 . Total costs of the different clinical pathways were calculated by adding ical pathways were calculated by adding the initial treatment and subsequent healththe initial treatment and subsequent healthcare resource use costs. Since the analysis care resource use costs. Since the analysis time horizon was 15 months, discounting time horizon was 15 months, discounting was not performed either for costs or for was not performed either for costs or for outcomes as it would not have had a outcomes as it would not have had a significant effect on the results. significant effect on the results.
The overall clinical and cost outcomes The overall clinical and cost outcomes were synthesised in the decision analysis. were synthesised in the decision analysis. Incremental cost-effectiveness ratios in Incremental cost-effectiveness ratios in terms of 'cost per additional successfully terms of 'cost per additional successfully treated patient' and 'cost per QALY gained' treated patient' and 'cost per QALY gained' were estimated by dividing the difference in were estimated by dividing the difference in the expected total healthcare costs of the the expected total healthcare costs of the two strategies by the difference in their two strategies by the difference in their overall effects (Table 2) . overall effects (Table 2) .
Sensitivity analyses Sensitivity analyses
Policy implications of cost-effectiveness Policy implications of cost-effectiveness point estimates are ambiguous. We treated point estimates are ambiguous. We treated the national unit cost data and assumptions the national unit cost data and assumptions of the cognitive-behavioural therapy protoof the cognitive-behavioural therapy protocol as fixed parameters, but extensive col as fixed parameters, but extensive sensitivity analysis was carried out to sensitivity analysis was carried out to explore the uncertainty around the different explore the uncertainty around the different input values and assumptions taken from input values and assumptions taken from the literature or based on the expert the literature or based on the expert opinion of the Guideline Development opinion of the Guideline Development Group. First, a univariate sensitivity Group. First, a univariate sensitivity analysis was carried out whereby single analysis was carried out whereby single parameters were varied between their parameters were varied between their plausible minimum and maximum values plausible minimum and maximum values while keeping all the other variables at their while keeping all the other variables at their base case values (Briggs & Sculpher, 1995 what would usually be provided in routine care by the NHSbe provided in routine care by the NHSsince most of the trials from which the since most of the trials from which the clinical effectiveness estimates were derived clinical effectiveness estimates were derived administered trial medication using this administered trial medication using this protocol. Recent clinical recommendations protocol. Recent clinical recommendations also support a more intensive management also support a more intensive management of antidepressant therapy than current of antidepressant therapy than current standard practice for patients with severe standard practice for patients with severe forms of depression (National Institute for forms of depression (National Institute for Clinical Excellence, 2004). We also Clinical Excellence, 2004). We also investigated the effect of adjusting for investigated the effect of adjusting for partial quality-of-life improvement in partial quality-of-life improvement in treatment-completer patients with no treatment-completer patients with no remission. Table 3 presents the ranges remission. Table 3 presents the ranges over which the different parameters were over which the different parameters were tested. tested.
To demonstrate the joint uncertainty To demonstrate the joint uncertainty between the different parameters and to esbetween the different parameters and to estimate the 95% uncertainty interval around timate the 95% uncertainty interval around the cost-effectiveness ratios, a probabilistic the cost-effectiveness ratios, a probabilistic analysis was conducted. Using the mean analysis was conducted. Using the mean parameter values and their 95% confidence parameter values and their 95% confidence intervals (see Table 1 ), appropriate distriintervals (see Table 1 ), appropriate distributions were assigned for each parameter butions were assigned for each parameter estimate. For example, beta distributions estimate. For example, beta distributions were used for probabilities and lognormal were used for probabilities and lognormal distributions for costs. The outcome and distributions for costs. The outcome and cost estimates were then recalculated cost estimates were then recalculated 10 000 times using Monte Carlo simulation 10 000 times using Monte Carlo simulation (Briggs (Briggs et al et al, 2002) . Whether an interven-, 2002). Whether an intervention is cost-effective or not depends on tion is cost-effective or not depends on how decision-makers value the additional how decision-makers value the additional health gain achieved by the treatment. health gain achieved by the treatment. The probability that combination therapy The probability that combination therapy is cost-effective compared with antidepresis cost-effective compared with antidepressant therapy alone as a function of sant therapy alone as a function of decision-makers' maximum willingness to decision-makers' maximum willingness to pay for an additional successfully treated pay for an additional successfully treated patient or QALY was illustrated by acceptpatient or QALY was illustrated by acceptability curves (Briggs & Gray, 1999) . ability curves (Briggs & Gray, 1999) .
RESULTS RESULTS
Outcomes Outcomes
Twenty-nine studies were included in the Twenty-nine studies were included in the original clinical systematic review of original clinical systematic review of cognitive-behavioural therapy (National cognitive-behavioural therapy (National Collaborating Centre for Mental Health, Collaborating Centre for Mental Health, 2005) . Out of these, seven trials compared 2005). Out of these, seven trials compared individual cognitive-behavioural therapy individual cognitive-behavioural therapy plus antidepressants with antidepressant plus antidepressants with antidepressant therapy alone in 831 patients with modertherapy alone in 831 patients with moderate or severe depression and provided data ate or severe depression and provided data on numbers not completing treatment: on numbers not completing treatment: Blackburn Blackburn et al et al (1981) (2000) and Thompson (2000) and Thompson et al et al (2001 ). Four (2001 . Four studies provided data on remission for studies provided data on remission for 646 patients with moderate or severe de-646 patients with moderate or severe depression at the end of treatment: Murphy pression at the end of treatment: Murphy et al et al (1984) , Elkin (1984) , Elkin et al et al (1989 ), Miller (1989 ), Miller et et al al (1989 and Keller (1989) and Keller et al et al (2000) . (2000). Subsequent reports of two trials provided Subsequent reports of two trials provided data on outcomes during 12-month data on outcomes during 12-month follow-up: Blackburn follow-up: Blackburn et al et al (1986) and (1986) and Simons Simons et al et al (1986) ; the latter reference is (1986); the latter reference is a follow-up report of the trial by Murphy a follow-up report of the trial by Murphy et al et al (1984) .
(1984). The probability of not completing The probability of not completing 3-month treatment was lower (risk 3-month treatment was lower (risk difference (RD) difference (RD)¼7 70.06, 95% CI 0.06, 95% CI 7 70.12 0.12 4 9 7 4 9 7 to 0.00) and the probability of not achievto 0.00) and the probability of not achieving remission during treatment was signifiing remission during treatment was significantly reduced (RD cantly reduced (RD¼7 70.18, 95% CI 0.18, 95% CI 7 70.36 to 0.00) with combination therapy 0.36 to 0.00) with combination therapy compared with antidepressant medication compared with antidepressant medication alone (Figs 2 and 3) . The follow-up studies alone (Figs 2 and 3) . The follow-up studies suggested that there is also lower risk of suggested that there is also lower risk of relapse with combination therapy relapse with combination therapy (RD (RD¼7 70.17, 95% CI 0.17, 95% CI 7 70.44 to 0.1) over 0.44 to 0.1) over a 12-month follow-up (Fig. 4) . The decision a 12-month follow-up (Fig. 4) . The decision analysis showed an overall 0.16 increase analysis showed an overall 0.16 increase per patient in the probability of successful per patient in the probability of successful treatment at the end of the 15-month analytreatment at the end of the 15-month analysis time horizon with combination therapy sis time horizon with combination therapy (see Table 2 ). (see Table 2 ).
The economic literature review identiThe economic literature review identified only one study with data on qualityfied only one study with data on qualityof-life weights appropriate for this decision of-life weights appropriate for this decision analysis. Revicki & Wood (1998) elicited analysis. Revicki & Wood (1998) elicited patient-assigned health state utilities by patient-assigned health state utilities by standard gamble technique for a variety of standard gamble technique for a variety of depression severity and different treatment depression severity and different treatment statuses with fluoxetine. Using these estistatuses with fluoxetine. Using these estimates, the average gain in QALYs was mates, the average gain in QALYs was calculated at 0.11 per patient with severe calculated at 0.11 per patient with severe depression and 0.04 per patient with depression and 0.04 per patient with moderate depression over the 15-month moderate depression over the 15-month analysis period (see Table 2 ). analysis period (see Table 2 ).
Costs and cost-effectiveness Costs and cost-effectiveness
The full cost of a 3-month course of antiThe full cost of a 3-month course of antidepressant therapy with standard care was depressant therapy with standard care was estimated as £162 at 2002-3 prices. The estimated as £162 at 2002-3 prices. The expected subsequent healthcare cost of expected subsequent healthcare cost of managing someone with moderate or severe managing someone with moderate or severe depression who did not respond to initial depression who did not respond to initial treatment was £580 for the analysis period. treatment was £580 for the analysis period. The expected cost of relapse within the The expected cost of relapse within the analysis time horizon was £417. The initial analysis time horizon was £417. The initial treatment cost of combination therapy was treatment cost of combination therapy was £1029 including the cost of a full course of £1029 including the cost of a full course of cognitive-behavioural therapy estimated at cognitive-behavioural therapy estimated at £867. Taking into consideration likely £867. Taking into consideration likely savings in subsequent healthcare use by savings in subsequent healthcare use by combination therapy, it is estimated that combination therapy, it is estimated that overall combination therapy would cost overall combination therapy would cost an extra £637 per patient when used for an extra £637 per patient when used for the routine treatment of moderate or severe the routine treatment of moderate or severe depression in specialist care during the depression in specialist care during the analysis period. The cost-effectiveness of analysis period. The cost-effectiveness of 4 9 8 4 9 8 combination therapy was calculated at combination therapy was calculated at £4056 per additional successfully treated £4056 per additional successfully treated patient, resulting in a cost of £5777 per patient, resulting in a cost of £5777 per QALY gained for severe depression and QALY gained for severe depression and £14 540 per QALY gained for moderate £14 540 per QALY gained for moderate depression (see Table 2 ). depression (see Table 2 ). Table 3 reports the results of the univariate Table 3 reports the results of the univariate sensitivity analysis. This indicates that the sensitivity analysis. This indicates that the results are robust to the investigated input results are robust to the investigated input parameters and assumptions. The costparameters and assumptions. The costeffectiveness estimates are most sensitive effectiveness estimates are most sensitive to the uncertainty around the difference in to the uncertainty around the difference in the risk of no remission at the end of treatthe risk of no remission at the end of treatment between the two treatment strategies. ment between the two treatment strategies.
Sensitivity analyses Sensitivity analyses
Other factors have a much lesser role in the Other factors have a much lesser role in the variation of the results. variation of the results. The probabilistic analysis showed that The probabilistic analysis showed that the 95% confidence interval around the the 95% confidence interval around the cost per additional successfully treated cost per additional successfully treated patient is between £1400 and £18 300. patient is between £1400 and £18 300. When taking patients' quality of life into When taking patients' quality of life into consideration, there is 97% probability that consideration, there is 97% probability that combination therapy is more cost-effective combination therapy is more cost-effective than antidepressant therapy alone for than antidepressant therapy alone for severe depression (95% CI £1900-33 800 severe depression (95% CI £1900-33 800 per QALY) and 88% probability for modper QALY) and 88% probability for moderate depression (95% CI £4800-79 400 erate depression (95% CI £4800-79 400 per QALY) at a recently quoted £30 000 per QALY) at a recently quoted £30 000 as decision-makers' maximum willingness as decision-makers' maximum willingness to pay per QALY in the UK (Richardson to pay per QALY in the UK (Richardson et al et al, 2004) . In contrast to severe depres-, 2004) . In contrast to severe depression, however, the probability of costsion, however, the probability of costeffectiveness for moderate depression is effectiveness for moderate depression is greatly affected by the maximum willinggreatly affected by the maximum willingness to pay value. At values lower than ness to pay value. At values lower than £30 000 per QALY, the uncertainty around £30 000 per QALY, the uncertainty around the cost-effectiveness of combination the cost-effectiveness of combination therapy greatly increases for patients with therapy greatly increases for patients with moderate depression (Fig. 5) . moderate depression (Fig. 5) .
DISCUSSION DISCUSSION
Assessment of the number of successfully Assessment of the number of successfully treated patients reveals an additional treated patients reveals an additional benefit of cognitive-behavioural therapy benefit of cognitive-behavioural therapy in combination with antidepressant therapy in combination with antidepressant therapy over pharmacotherapy alone which is over pharmacotherapy alone which is similar for both moderate and severe desimilar for both moderate and severe depression. However, the decision analysis pression. However, the decision analysis predicts that when patients' quality of life predicts that when patients' quality of life is also included, there are greater gains for is also included, there are greater gains for 4 9 9 4 9 9 Cost-effectiveness acceptability curves: probability that combination therapy is cost-effective as a Cost-effectiveness acceptability curves: probability that combination therapy is cost-effective as a function of decision-makers' willingness to pay per additional unit of health gain.QALY, quality-adjusted life-year. function of decision-makers' willingness to pay per additional unit of health gain.QALY, quality-adjusted life-year.
patients with severe depression compared patients with severe depression compared with moderate depression. The cost results with moderate depression. The cost results suggest that although the initial treatment suggest that although the initial treatment cost of combination therapy is substantially cost of combination therapy is substantially higher, these costs are in part offset by higher, these costs are in part offset by savings accruing from lower treatment savings accruing from lower treatment costs in the subsequent year. Overall, the costs in the subsequent year. Overall, the evaluation shows that combination therapy evaluation shows that combination therapy is likely to be a cost-effective first-line secis likely to be a cost-effective first-line secondary care treatment for severe depresondary care treatment for severe depression. It is, however, much more uncertain sion. It is, however, much more uncertain from the currently available evidence from the currently available evidence whether its first-line secondary care use is whether its first-line secondary care use is cost-effective for moderate depression. Folcost-effective for moderate depression. Following from these results, it is also likely lowing from these results, it is also likely that targeting combination therapy on sethat targeting combination therapy on severe forms of depression could be a more vere forms of depression could be a more efficient way of using limited resources. efficient way of using limited resources.
Generalisability of the results
Although the cost-effectiveness estimates Although the cost-effectiveness estimates were based on costs from the UK, the effecwere based on costs from the UK, the effectiveness data were synthesised from a range tiveness data were synthesised from a range of different countries and healthcare sysof different countries and healthcare systems. In the case of high-income countries, tems. In the case of high-income countries, the relative costs and benefits of the differthe relative costs and benefits of the different interventions (in particular the psychoent interventions (in particular the psychological treatment) are expected to be logical treatment) are expected to be similar. Therefore the findings of this study similar. Therefore the findings of this study are likely to be generalisable across highare likely to be generalisable across highincome countries. However, different counincome countries. However, different countries have different thresholds for society's tries have different thresholds for society's maximum willingness to pay per additional maximum willingness to pay per additional health benefit, which may affect the decihealth benefit, which may affect the decision to provide combination therapy as sion to provide combination therapy as first-line treatment for either moderate or first-line treatment for either moderate or severe depression. severe depression.
Limitations of the analysis Limitations of the analysis
In our study clinical effectiveness estimates In our study clinical effectiveness estimates were based on efficacy data obtained from were based on efficacy data obtained from randomised controlled trials, and so it is randomised controlled trials, and so it is possible that the probability of successful possible that the probability of successful outcome is overestimated for both treatoutcome is overestimated for both treatment options provided within standard ment options provided within standard NHS care. It is anticipated, however, NHS care. It is anticipated, however, that this does not influence the relative that this does not influence the relative effectiveness of the compared interventions effectiveness of the compared interventions significantly. Since a number of the significantly. Since a number of the included studies were conducted during included studies were conducted during the 1980s, issues may also arise regarding the 1980s, issues may also arise regarding current applicability of the synthesised clincurrent applicability of the synthesised clinical evidence. The results of more recent ical evidence. The results of more recent studies (for example, Keller studies (for example, Keller et al et al, 2000) , 2000) suggest that this is not the case. suggest that this is not the case.
As with previous studies, we defined As with previous studies, we defined successful treatment as achieving remission successful treatment as achieving remission at the end of 3-month treatment and no reat the end of 3-month treatment and no relapse during 12-month follow-up, but in lapse during 12-month follow-up, but in the sensitivity analysis we also investigated the sensitivity analysis we also investigated the effect of partial response to treatment the effect of partial response to treatment when quality of life was included. Current when quality of life was included. Current evidence on the health-related quality of life evidence on the health-related quality of life of people with depression, however, is very of people with depression, however, is very scarce. Therefore, revision of all the QALY scarce. Therefore, revision of all the QALY estimates will be necessary when more estimates will be necessary when more utility information becomes available. utility information becomes available. Furthermore, some clinical evidence also Furthermore, some clinical evidence also indicates lower relapse rates with combinaindicates lower relapse rates with combination therapy for up to 6 years after treattion therapy for up to 6 years after treatment (Scott ment (Scott et al et al, 2003) . It would have , 2003). It would have been desirable to evaluate the different been desirable to evaluate the different strategies over a longer period but we were strategies over a longer period but we were unable to extend our evaluation this far unable to extend our evaluation this far because of lack of direct clinical evidence because of lack of direct clinical evidence beyond 15 months. beyond 15 months.
Regarding the limitations of the cost Regarding the limitations of the cost difference estimates, individual cognitivedifference estimates, individual cognitivebehavioural therapy is a relatively behavioural therapy is a relatively resource-intensive psychological treatment. resource-intensive psychological treatment. In future, clinical research may define and In future, clinical research may define and develop less resource-intensive but similarly develop less resource-intensive but similarly effective forms of psychological therapy to effective forms of psychological therapy to be used in combination with antibe used in combination with antidepressants, thereby improving costdepressants, thereby improving costeffectiveness. It is unlikely that the choice effectiveness. It is unlikely that the choice of antidepressant would have influenced of antidepressant would have influenced the cost difference between the combinathe cost difference between the combination and the pharmacotherapy strategies tion and the pharmacotherapy strategies substantially, since the assumed medication substantially, since the assumed medication protocol is identical in the two strategies. protocol is identical in the two strategies. Similar reasoning is likely to be valid for Similar reasoning is likely to be valid for the cost consequences of maintenance antithe cost consequences of maintenance antidepressant therapy over and above the initidepressant therapy over and above the initial 3-month treatment. This option was not al 3-month treatment. This option was not tested because of the lack of appropriate tested because of the lack of appropriate comparative clinical evidence. comparative clinical evidence.
Depression incurs significant nonDepression incurs significant nonhealthcare costs such as social service costs, healthcare costs such as social service costs, direct costs to patients and their families direct costs to patients and their families and lost productivity costs due to morbidity and lost productivity costs due to morbidity or premature mortality (Knapp & Ilson, or premature mortality (Knapp & Ilson, 2002) . As the present analysis was carried 2002). As the present analysis was carried out from the perspective of the healthcare out from the perspective of the healthcare sector, these non-healthcare costs were not sector, these non-healthcare costs were not considered. Had we included them, it is considered. Had we included them, it is likely that the cost-effectiveness of combilikely that the cost-effectiveness of combination therapy would have improved. All nation therapy would have improved. All the described limitations of the clinical the described limitations of the clinical and cost difference evidence suggest that and cost difference evidence suggest that current results of the decision model should current results of the decision model should be rather treated as conservative. be rather treated as conservative.
Guideline recommendations Guideline recommendations
Based on the clinical and cost-effectiveness Based on the clinical and cost-effectiveness evidence and the availability and likely evidence and the availability and likely affordability of the different treatment affordability of the different treatment options within the NHS, the NICE guideoptions within the NHS, the NICE guideline (National Institute for Clinical Excelline (National Institute for Clinical Excellence, 2004) recommends combination lence, 2004) recommends combination therapy when patients present initially with therapy when patients present initially with severe depression. Antidepressants are the severe depression. Antidepressants are the recommended first-line treatment for those recommended first-line treatment for those with moderate depression, with combinawith moderate depression, with combination therapy as second-line intervention. tion therapy as second-line intervention. Considering the importance of patient preConsidering the importance of patient preference, recommendations are also made ference, recommendations are also made about the use of psychological intervenabout the use of psychological interventions, including combination treatment, tions, including combination treatment, where patients declined the offer of antiwhere patients declined the offer of antidepressant medication alone or had predepressant medication alone or had previously not responded to antidepressant viously not responded to antidepressant medication. The consequent increase in medication. The consequent increase in the uptake of psychological treatments for the uptake of psychological treatments for people with severe depression and moderpeople with severe depression and moderate depression that has not responded to ate depression that has not responded to antidepressants is likely to require addiantidepressants is likely to require additional resources in the NHS, mostly the cost tional resources in the NHS, mostly the cost and time implications of extra staff training and time implications of extra staff training and employment. These are currently under and employment. These are currently under consideration by NICE and the NHS in consideration by NICE and the NHS in England and Wales. England and Wales.
